Home/Filings/4/0001193125-26-018317
4//SEC Filing

Simon Mark 4

Accession 0001193125-26-018317

CIK 0001759138other

Filed

Jan 20, 7:00 PM ET

Accepted

Jan 21, 6:53 PM ET

Size

5.6 KB

Accession

0001193125-26-018317

Research Summary

AI-generated summary of this filing

Updated

Cabaletta Bio (CABA) Director Simon Mark Buys 11,061 Shares

What Happened
Director Simon Mark made an open-market purchase of 11,061 shares of Cabaletta Bio (CABA) on January 21, 2026. The transaction was reported as a purchase (code P) with a weighted-average price of $2.28 per share, for a total cost of approximately $25,261. This filing does not state the insider’s motive; purchases are often viewed by investors as a more informative/positive signal than routine sales, but no conclusion about intent should be drawn.

Key Details

  • Transaction date: 2026-01-21
  • Transaction type: Open-market purchase (Code P)
  • Shares acquired: 11,061
  • Price: Weighted average $2.28 per share; actual prices ranged from $2.245 to $2.32 (see footnote)
  • Total reported value: ~$25,261
  • Shares owned after transaction: Not disclosed in this Form 4
  • Footnote: The reported price is a weighted average; the purchaser can provide the exact breakdown of shares bought at each price within the $2.245–$2.32 range upon request (per filing)
  • Timeliness: Filed for the transaction dated the same day (no late filing indicated)

Context

  • This was a direct stock purchase (not an option exercise, award, or gift).
  • Purchases by insiders can signal confidence, but filings do not explain motivation; consider alongside other filings and company news.

Insider Transaction Report

Form 4
Period: 2026-01-21
Simon Mark
Director
Transactions
  • Purchase

    Common Stock

    [F1]
    2026-01-21$2.28/sh+11,061$25,261147,205 total
Holdings
  • Common Stock

    (indirect: By Spouse)
    7,000
Footnotes (1)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were purchased at prices ranging from $2.245 to $2.32, inclusive. The reporting person has provided to the Issuer, and undertakes to provide any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Signature
By: /s/ Michael Gerard, as Attorney-in-Fact|2026-01-21

Documents

1 file

Issuer

Cabaletta Bio, Inc.

CIK 0001759138

Entity typeother

Related Parties

1
  • filerCIK 0001400717

Filing Metadata

Form type
4
Filed
Jan 20, 7:00 PM ET
Accepted
Jan 21, 6:53 PM ET
Size
5.6 KB